logo
Survivors of CIA-linked mind-control tests in Montreal win right to sue McGill, Ottawa

Survivors of CIA-linked mind-control tests in Montreal win right to sue McGill, Ottawa

A Quebec Superior Court judge has authorized a class-action lawsuit against McGill University, the Royal Victoria Hospital, and the federal government over decades-old psychiatric experiments that allegedly left hundreds of patients with permanent psychological damage.
The ruling opens the door for survivors and their families to seek compensation for what they describe as 'unlawful human experimentation' at Montreal's Allan Memorial Institute between 1948 and 1964.
The research was led by Dr. Ewen Cameron, a once-renowned psychiatrist who employed now-discredited techniques such as intensive electroconvulsive therapy, sensory deprivation, drug-induced comas, and repeated audio messages — sometimes between 250,000 and 500,000 times — in a controversial method he called 'depatterning.'
Patients say they were subjected to these treatments without informed consent or even knowing they were part of experimental research.
Justice Dominique Poulin ruled that two applicants, Lana Ponting and Julie Tanny, had presented sufficient evidence that they or their relatives had undergone depatterning treatments at the Allan Memorial. A third applicant, Patricia Edwards Roberge, was not granted representative status, although she and her late mother may still be eligible class members.
The court heard that Tanny's father was admitted to the institute for facial pain in 1957, and underwent drug-induced sleep treatment over several weeks. When he returned home, he was described by his daughter as being in 'a childlike state,' emotionally detached, and volatile. He later died by suicide.
Ponting was 15 years old when she was admitted in 1958, reportedly for being 'disobedient.'
She said that she was given unidentified pills and later underwent electroshock therapy and 'psychic driving.' She says she left the institute with memory loss and long-term psychological impacts, including flashbacks and depression.
The plaintiffs allege that the experiments were enabled by McGill and the Royal Victoria Hospital, and funded in part by the federal government through the Department of National Health and Welfare.
The court found that these claims were sufficiently specific and supported by documentary evidence to allow a class action to proceed.
Justice Poulin also rejected arguments that the action was 'prescribed' — or too old to be heard — adding that the nature of the experiments and the lack of transparency meant many victims could not have discovered what happened until decades later.
The court authorized the plaintiffs to pursue compensatory damages, but denied claims for punitive damages, noting that the events predated the adoption of Quebec's Charter of Human Rights and Freedoms.
The case is now expected to move to trial, where the court will decide whether damages should be awarded.
This story was originally published July 31, 2025 at 1:55 PM.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Winnipeg woman brainwashed in Montreal psychiatric hospital hospital seeks apology
Winnipeg woman brainwashed in Montreal psychiatric hospital hospital seeks apology

CTV News

time4 days ago

  • CTV News

Winnipeg woman brainwashed in Montreal psychiatric hospital hospital seeks apology

Lana Ponting, seen on Aug. 14, 2025, was part of the infamous MK-ULTRA program. (Daniel Halmarson/CTV News Winnipeg) Lana Ponting was only 16 years old when she was hospitalized at Montreal's Allan Memorial Institute on the campus of McGill University. Ponting said she was admitted by her parents to the psychiatric hospital in 1958 after she ran away from home several times. 'I had behaviour problems like any normal teenager and I guess they thought putting me into the Allan would help me and help them,' Ponting told CTV News Winnipeg. The now 84-year-old, who lives in Winnipeg, spent a month under the care of psychiatrist Ewen Cameron. 'I've been sick all my life because of what they did to me,' Ponting said. 'And sometimes I wake up in the night screaming.' Unknowingly, Ponting was part of the infamous MK-ULTRA program, a Cold War era CIA project partially funded by the Canadian government. Ponting said she was forced to take drugs like LSD and subjected to a series of mind control and brainwashing experiments. 'We never [gave] consent. They just did what they wanted to us—we were guinea pigs.' In late July, a Quebec Superior Court judge authorized a class-action lawsuit against McGill University, Montreal's Royal Victoria Hospital, and the Government of Canada. Ponting is a representative plaintiff in the suit, which alleges hundreds of patients like her were subjected to experiments without their consent or knowledge. Ponting said Ottawa needs to apologize for the harm done and the lawsuit is seeking compensation. 'I don't look at myself as a hero,' Ponting explained. 'I look at myself as an 84-year-old woman who will talk. I will not shut up for anyone.' McGill University and the federal government didn't respond to requests seeking comment on the lawsuit.

Weight-loss drugs show promise for other diseases, study shows
Weight-loss drugs show promise for other diseases, study shows

CTV News

time09-08-2025

  • CTV News

Weight-loss drugs show promise for other diseases, study shows

A new study reveals that weight-loss drugs like Ozempic may help treat conditions such as Parkinson's disease, and addiction. The injectable drug Ozempic is shown, July 1, 2023, in Houston. (AP Photo/David J. Phillip, File) Weight loss drugs like Ozempic and Wegovy could help treat heart failure, Parkinson's disease and even addiction, according to a new study from McGill University and the Jewish General Hospital. The research, published in eClinicalMedicine, reviewed evidence from dozens of studies to assess whether GLP-1 drugs could be beneficial in treating other illnesses. Areesha Moiz, a research assistant at the Centre of Clinical Epidemiology at the Lady Davis Institute, part of the Jewish General, said some of the findings were surprising. 'It's quite interesting to see the pleiotropic benefits of this drug beyond what it was designed for,' Moiz said in a recent interview. She noted researchers wanted to create a roadmap showing where the science is headed regarding GLP-1 drugs. According to Moiz, the benefits of GLP-1 drugs like Ozempic are now well established in patients with obesity-related cardiovascular and kidney disease. Additionally, ongoing clinical studies are investigating their effectiveness in conditions commonly associated with obesity, such as heart failure, sleep apnea, liver disease and knee osteoarthritis. 'But what's actually interesting is that we found other conditions. We found neurodegenerative diseases, like Alzheimer's and Parkinson's, that are also being investigated, as well as addiction, meaning substance abuse disorders,' Moiz said. 'Some of these are linked somewhat to the weight-loss effects, but there are also other mechanisms at play here that are independent of weight loss, which are actually providing some beneficial outcomes in certain populations.' Moiz explained that GLP-1 receptors are found throughout the body, affecting multiple organ systems. For example, in type 2 diabetes, these drugs act on receptors in the pancreas, brain and gut, slowing digestion and suppressing appetite, which leads to weight loss. 'There's a certain mechanism where it acts on the reward system of the brain, so that kind of brings down the pleasurable effect of eating. But that's also kind of related to addiction, right? 'Like alcohol abuse, cigarette smoking, opioid abuse — all of that kind of ties together. So that's why, because of these receptors found in these underlying mechanisms, they're being investigated for other conditions that might also be related to these biological rationales,' she said. As more benefits are uncovered, Moiz said that serious risks previously feared have largely been ruled out by recent studies. Nevertheless, side effects, especially gastrointestinal, have been observed. 'There are some side effects related to the gallbladder, which have to do with the slowing down the digestion and the rapid weight loss. But this is not as common as you expect,' Moiz said. 'Recently, there were some signals for optic neuropathy and for aspiration risk, but these are, again, very, very rare side effects, and there haven't been big trials that were designed to really look at this, so we can't say that the drugs are causing this.' GLP-1 drugs are quite expensive and are not currently covered by Quebec's public drug plan unless it is prescribed for diabetes. So Moiz said the first step in making it more accessible is for obesity to be declared a chronic condition by the province, like Alberta did this year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store